Drug intelligence / Profile preview

1711(scFv)-SNAP-IR700

Development stage: Preclinical
Lead developer: University of Cape Town
Modality: scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intratumoral, Intravenous

Overview

1711(scFv)-SNAP-IR700 is a research-stage photoimmunotherapy (NIR-PIT) agent designed for the targeted treatment of EGFR-expressing malignancies. It consists of a human single-chain variable fragment (scFv), designated '1711' and derived from the monoclonal antibody panitumumab, fused to a SNAP-tag protein. This fusion protein is site-specifically conjugated to IR700 (IRDye 700DX), a near-infrared phthalocyanine photosensitizer, using the self-labeling properties of the SNAP-tag enzyme. The agent selectively binds to the epidermal growth factor receptor (EGFR) on the surface of cancer cells. Upon irradiation with near-infrared light, the IR700 moiety is activated, inducing rapid cell membrane damage and immunogenic cell death. This compound has been investigated in preclinical models of melanoma and other EGFR-positive solid tumors as a potential strategy to overcome chemoresistance and reduce systemic side effects compared to traditional therapies.

Other names: 1711-scFv-SNAP-IR700panitumumab 1711-scFv-SNAP-IR700panitumumab1711-scFv-SNAP-IR700panitumumab-1711-scFv-SNAP-IR700

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on 1711(scFv)-SNAP-IR700.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1711(scFv)-SNAP-IR700.

Explore the full profile